Novo Nordisk
Ovation.io Collecting WGS, Clinical Data From 8,500 Patients on GLP-1 Meds
The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role for biomarkers to guide their use.
NanoVation Therapeutics, Novo Nordisk to Develop Base-Editing Therapies for Rare Diseases
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.
Novo Nordisk Scoops up 2seventy's Hemophilia A Program, Gene Editing Technology
The deal, which is worth up to $40 million, will allow 2seventy to maintain its focus on advancing the multiple myeloma CAR T-cell therapy Abecma.